Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 10/09/20251 min de lecture
Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers
Traduction automatique locale · Langue originale de la source
Résumé
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →